

ERS Research Seminar
Lung Cancer Screening: from Trial to Practice

11 – 12 December 2018
Barcelona, Spain

Tuesday, 11 December 2018

08.30 – 09.00 Registration

09.00 – 09.15 Introduction and welcome
Jan van Meerbeeck and Annemie Snoeckx

Session I – Lung cancer screening: what do we know, what don't we know

Chairs: Guido van Hal

09.15 – 09.45 NELSON: the Trafalgar of lung cancer screening?
Harry De Koning (Netherlands)

09.45 – 10.15 How to best target the hard-to-reach? The UK-experience?
Samantha Quaiife (UK)

10.15 – 10.40 General discussion

10.40 – 11.00 *Coffee break*

11.00 – 12.00: Session II – Break out session 1: define per country or per 2 countries

1: How is screening of cancer in general organized in your country?

2: Who are the stakeholders for lung cancer screening implementation in your country?

3: What are the necessary steps for lung cancer screening implementation in your country?

12.00 – 12.30 Plenary report of break out groups

Chairs: Mina Gaga and Torsten Blum

12.30 – 13.30 *Lunch Break*

Session III – Implementation in Europe: hurdles and steps

Chairs: John Field and Annemie Snoeckx

13.30 – 13.50 Participation in screening: lessons learned from the past
Guido Van Hal (Belgium)

13.50 – 14.10 Public understanding and informed decision making: keys to a successful screening programme
David Ritchie (Belgium)

14.10 – 14.30 How to involve GP's: an essential component of recruitment – Speaker TBC

14.30 – 14.50 The role of patient advocacy groups in implementation
Bert van Herk (Netherlands)

14.50 – 15.15 Where does the EU go from here?
EU commissioner DG Health and Consumer Protection

15.15 – 15.40 General discussion

15.40 – 16.00 *Coffee break*

Session IV – Risk assessment strategies

Chairs: Harry De Koning and Torsten Blum

- 16.00 – 16.20 Risk assessment scores: a critical appraisal
Hans-Ulrich Kauczor (Germany)
- 16.20 – 16.40 Smoking cessation strategies and outcomes – Speaker TBC
- 16.40 – 17.00 Breathomics: an extra nose to detect lung cancer?
Marc van der Schee (Netherlands)
- 17.00 – 17.20 Blood biomarkers: ready for practice?
John Field (UK)
- 17.20 – 17.45 Discussion
- 17.45 – 18.00 Summary of the day /introduction to day 2
Jan van Meerbeeck (Belgium)

Wednesday, 12 December 2018

08.30 – 10.00: Session V – Break out session 2: standardisation

Group 1: Recruitment implementation - Chair: Jan van Meerbeeck

Can we define a minimum common risk assessment strategy for Europe?

Group 2: Technical implementation - Chairs Annemie Snoeckx and Hans-Ulrich Kauczor

Can we define a common minimal SOP for nodule handling and follow up?

10.00 – 10.30 *Coffee break*

10.30 – 11.00: Report from break out groups

Chair: Hans-Ulrich Kauczor

Session VI – From trial to practice: concerns of different stakeholders

Chairs: John Field and Hans-Ulrich Kauczor

- 11.00 – 11.20 What to do with all those pulmonary nodules referred to the pulmonologist?
– *Speaker TBC*
- 11.20 – 11.40 How will lung cancer screening impact our daily practice? A radiologist's view
Annemie Snoeckx (Belgium)
- 11.40 – 12.00 Artificial Intelligence: an extra clinician we can not ignore
Bram Van Ginneken (Netherlands)
- 12.00 – 12.20 The surgeon's point of view
Anna Elisabeth Frick (Belgium)
- 12.20 – 12.45 General discussion
- 12.45 – 13.15 *Summing up: remarks, conclusions and action points*
- 13.15 – 14.00 *Lunch and farewell*
- 14.00 – 15.00 **Private meeting – KOL's prepare summary of the meeting**
Finalizing the ESR-ERS White paper on screening
Finalizing the White paper co-authors